ESM1 and neoplasm: ESM1 can activate the downstream MAPK/ERK signaling pathway by binding to the c-Met membrane receptor of vascular endothelial cells and can promote the expression of HIF1α, VEGFA, MMP9, and other pro-angiogenic factors, thereby promoting tumor angiogenesis and peritoneal metastasis.